logo-loader

Oncimmune says revenues in line

Published: 08:17 04 Jun 2020 BST

Oncimmune -
The group's earlyCDT test was selected last year by a big pharma company to detect lung cancer in at-risk smokers

Oncimmune Holdings PLC (LON:ONC) said it is expecting further strong growth in the top-line in the current fiscal year.

In a trading update covering the 12 months to the end of May 2020, the immunodiagnostics specialist noted that its revenue was in line with market expectations.

Meanwhile, it said, the next 18 months are expected to create substantial revenues within the EarlyCDT lung cancer test business. while the pipeline of contracts within the ImmunoINSIGHTS services business is building.

“We can look with confidence into FY [fiscal] 2021 and beyond,” the group added in the statement.

Cash at the end of the fiscal year was around £4.2mln and net debt stood at roughly £3.1mln.

Oncimmune also noted that its board has been streamlined, as a result of which Geoffrey Hamilton-Fairley, the non-executive vice-chairman and co-founder of the company, plus two other non-executive directors - Julian Hirst and Carsten Schroeder - have stepped down from the board with immediate effect.

"Following the launch of our three-year forward strategy, announced in late 2018, we have undertaken a ground-up assessment, identifying and capitalising upon the wide range of opportunities presented by Oncimmune's proprietary autoantibody-based platform built up over the past fifteen years; exploiting both its depth through novel indications, and its breadth across the entire patient care pathway,” Adam Hill, the chief executive officer of Oncimmune said in the update

"We firmly believe that the momentum we are now building from the foundations laid over the last 12 months validates our strategy and underpins the future commercial potential of our business,” he added.

Shares in Oncimmune were up 3.1% at 116p in early deals.

Oncimmune's strategic pivot aims for robust growth in 2024

Oncimmune Holdings PLC (AIM:ONC) CEO Martin Gouldstone joins Proactive's Stephen Gunnion with highlights of the company's 2023 performance, which included its strategic decision to focus on its ImmunoINSIGHTS platform. A significant development was the sale of its early lung cancer detection...

1 week, 6 days ago